Nine immune checkpoint-related genes (CD80, CD86, LAG3, CD274, CTLA4, PDCD1, LGALS3, CD200R1, and KIR3DL1) were significantly upregulated in the high-risk group (Figure 9C), suggesting that high-risk patients may be more suitable for immune checkpoint inhibitor therapy.ESTIMATE analysis of TCGA cancer samples revealed significant differences between high-risk and low-risk patient groups. The gene discussed is KIR3DL1; the disease is cancer.